Key considerations for dosimetry from non clinical to clinical application

Pharmaron hosted a focused, real-world discussion on what goes into a dosimetry assessment, starting from early non-clinical studies through to its role in clinical trial design.

This on-demand webinar explores how dosimetry helps determine safe radioactive dosing, supports regulatory submissions, and influences how radiolabeled studies are planned.

What does the webinar cover?

• An introduction to dosimetry assessment
  • Theory and applications of dosimetry assessment​
  • International exposure limits for radiolabelled clinical studies​
• Non-clinical considerations/study design
  • Overview of required non-clinical studies and how they inform study design
  • How the ADME properties of the radiolabel can impact dosimetry results​
• Clinical Application of Dosimetry Assessment
  • How dosimetry reports guide radioactive dose selection
  • Key considerations for designing radiolabeled clinical studies

The speakers

• Dennis Heller​ – Director, Early Drug Development Services at Certara​
• Iain Shaw​ – Senior Director, ¹⁴C Enabled Drug Development at Quotient Sciences ​
• Claire Henson​ – Team Leader in Pharmaceutical Metabolism at Pharmaron
• Moderated by Ragu Ramanathan – Vice President, DMPK Business Operations at Pharmaron